Exactech, a major manufacturer of joint replacement devices, is facing one of the largest medical device mass tort litigations in the United States, with over 1,800 pending lawsuits filed by patients who received defective polyethylene knee, hip, and ankle implants. The core of the problem centers on defective polyethylene liners that deteriorated prematurely due to oxidation, causing implant failures that often required painful revision surgeries for patients who thought their replacement joints would last 15 to 20 years or more.
As of February 2026, no patient settlements or verdicts have been finalized, though the federal government secured an $8 million settlement with Exactech in September 2025 over allegations that the company knowingly sold defective implants to Medicare, Medicaid, and the Veterans Administration. The litigation encompasses roughly 150,000 patients who received affected Exactech devices manufactured between 2004 and August 2021, making this a widespread problem that has disrupted the lives of hundreds of thousands of Americans who trusted that their joint replacement surgery would solve their mobility problems. Beyond the federal settlement, patients are now waiting to see how much compensation they will receive for the costs of revision surgeries, pain and suffering, lost wages, and diminished quality of life—with preliminary projections suggesting settlements could range from $50,000 to $300,000 or more per claimant, though these figures remain unconfirmed.
Table of Contents
- WHAT ARE EXACTECH POLYETHYLENE LINER DEFECTS AND WHY DID THEY FAIL?
- THE SCOPE AND SCALE OF THE PROBLEM: HOW MANY PATIENTS WERE AFFECTED?
- WHAT DID THE FEDERAL GOVERNMENT FIND, AND WHAT DOES THE DOJ SETTLEMENT MEAN?
- YOUR OPTIONS IF YOU RECEIVED AN EXACTECH IMPLANT: WHAT CAN YOU DO?
- UNDERSTANDING SETTLEMENT PROJECTIONS AND COMPENSATION AMOUNTS
- THE BANKRUPTCY AND TIMELINE: HOW DID WE GET HERE?
- UPCOMING BELLWETHER TRIALS AND THE PATH FORWARD
WHAT ARE EXACTECH POLYETHYLENE LINER DEFECTS AND WHY DID THEY FAIL?
Exactech’s defective polyethylene liners were part of the company’s GENUine, Trident, and other joint replacement systems used in knee, hip, and ankle surgeries. The specific defect involved the vacuum-sealed packaging used to store these polyethylene liners before surgery: the packaging lacked an EVOH (ethylene vinyl alcohol) oxygen barrier, which is designed to keep oxygen from reaching the plastic component during storage. Without this barrier, the polyethylene became oxidized—essentially damaged by oxygen exposure—while sitting on hospital shelves and in storage facilities, sometimes for years before implantation. This oxidation weakened the material, causing the liners to crack, wear excessively, and fail far more quickly than the 15 to 20 years patients and surgeons expected.
Unlike other joint replacement components made of metal, polyethylene liners serve as the bearing surface in knee and hip replacements, absorbing the friction and impact of normal walking and movement. When these liners fail due to premature oxidation, they don’t just become less effective—they degrade into small particles that trigger an inflammatory immune response in the body. For patients, this means chronic pain, swelling, reduced mobility, and the need for expensive and painful revision surgery to replace the failed component, often just 5 to 8 years after the original implant. Consider the case of a 62-year-old who received an Exactech knee replacement in 2013 with the expectation that it would last through her remaining active years; by 2018, she was experiencing severe pain caused by liner failure and required another surgical procedure, losing months to recovery and facing the ongoing risk of additional failures with her current implant.
THE SCOPE AND SCALE OF THE PROBLEM: HOW MANY PATIENTS WERE AFFECTED?
The defect affected approximately 150,000 patients across the United States, with the FDA issuing a formal warning in March 2023 regarding all Exactech joint replacement devices manufactured between 2004 and August 2021. This 17-year window of potentially defective products means that surgeons and patients have had difficulty determining exactly which implants are at risk, since devices manufactured in 2005 and those made in 2020 both fell within the affected timeframe. Hospitals and surgical centers nationwide distributed these implants across every state, though litigation has been particularly concentrated in federal multidistrict litigation (MDL-3044) in the U.S. District Court for the Eastern District of New York and in consolidated Florida state court proceedings. The sheer number of affected patients distinguishes this litigation from many other medical device cases, where defects might touch hundreds or thousands of people.
Here, 150,000 patients have been harmed, meaning the problem is systemic and widespread rather than isolated to a small batch or manufacturing run. As of February 2026, federal courts have consolidated 1,838 pending lawsuits in the Eastern District of New York alone, with Judge Nicholas G. Garaufis presiding, while over 700 additional cases are pending in consolidated Florida state court proceedings. The fact that so many patients are affected also means that it will take years to work through all the litigation, settle claims, and get compensation to those who need it. Many patients cannot afford the out-of-pocket costs of revision surgery and are struggling financially while waiting for their cases to move forward.
WHAT DID THE FEDERAL GOVERNMENT FIND, AND WHAT DOES THE DOJ SETTLEMENT MEAN?
In September 2025, the U.S. Department of Justice announced an $8 million settlement with Exactech over allegations that the company knowingly sold defective implants to Medicare, Medicaid, and the Veterans Administration. According to the DOJ’s allegations, Exactech had knowledge of high failure rates in some of its components as early as 2006—nearly two decades before the FDA warning and at least 15 years before the company implemented corrective packaging measures. The settlement reflects a finding that Exactech violated the False Claims Act by submitting claims for defective products to federal health programs while concealing information about their poor performance.
However, it is critical to understand that the $8 million federal settlement does not resolve individual patient lawsuits and does not compensate any affected patients directly. The settlement goes to the federal government to reimburse Medicare, Medicaid, and the VA for payments they made on defective implants. This distinction is essential: while the DOJ settlement confirms that the government believes Exactech knowingly sold defective products, patients harmed by those products must pursue their own separate lawsuits to seek compensation for medical expenses, pain and suffering, and other damages. Many patients have been disappointed to learn that the federal settlement, while vindicating their concerns that Exactech knew about the problems, does not put money in their pockets and does not resolve the litigation they initiated.
YOUR OPTIONS IF YOU RECEIVED AN EXACTECH IMPLANT: WHAT CAN YOU DO?
If you received an Exactech joint replacement with a polyethylene liner manufactured between 2004 and August 2021, you have several important options to consider. First, contact your surgeon or the hospital where you received your implant to confirm the exact date your device was manufactured and obtain your implant documentation. This information will determine whether your specific implant falls within the affected date range and what your legal options are. Many patients have already filed lawsuits as part of the federal MDL-3044 consolidation in New York or the Florida state court proceedings, and attorneys specializing in medical device litigation are actively recruiting clients for these actions.
The litigation landscape includes both the federal MDL case and state court cases, meaning that the path your claim follows depends on where you live and where you choose to file. Some patients have attorneys working on contingency, meaning you pay nothing upfront and your attorney’s fees come from your settlement or award if you prevail. This arrangement makes it financially possible for patients to pursue claims without immediate out-of-pocket legal costs. However, you should understand that litigation is slow—these cases can take years to settle or go to trial—and there is no guarantee of compensation. You may also want to consult with your own independent medical expert about whether your current symptoms are caused by the defective implant, as this documentation strengthens any claim you file.
UNDERSTANDING SETTLEMENT PROJECTIONS AND COMPENSATION AMOUNTS
While no patient settlements have been finalized as of February 2026, preliminary projections suggest that settlement amounts could range between $50,000 and $300,000 per claimant, with more serious cases or those involving multiple surgeries potentially exceeding $300,000. These projections are based on similar medical device litigation settlements and the severity of each patient’s injuries, but they should be understood as estimates only. The actual compensation any individual patient receives depends on many factors, including the number of claims filed, the strength of their individual case, the outcome of bellwether trials, and what the parties agree to in settlement negotiations. A critical limitation of these projections is that they are not guaranteed or binding.
Some patients may receive significantly less, while others might receive more, depending on the specific facts of their case and how judges or juries evaluate damages. Additionally, once a settlement is reached, the total compensation is typically divided among all claimants, meaning that if an unexpectedly large number of patients file claims, individual awards might be reduced. Patients should also be aware that settlement amounts usually decrease further after attorney fees and litigation costs are deducted, so the net amount you receive in your bank account will be less than the headline settlement figure. For example, if you receive a $100,000 settlement but your attorney’s contingency fee is 25-30% and litigation costs are $5,000, your net recovery would be approximately $65,000 to $70,000.
THE BANKRUPTCY AND TIMELINE: HOW DID WE GET HERE?
Exactech filed for Chapter 11 bankruptcy on October 29, 2024, in response to the mounting lawsuits and the growing financial liability posed by the defective implant litigation. The bankruptcy filing temporarily paused litigation against the company, as federal bankruptcy law imposes an “automatic stay” that prevents creditors and plaintiffs from pursuing lawsuits during the bankruptcy process. However, the bankruptcy did not eliminate patient claims—instead, it shifted them into the bankruptcy proceeding, where a bankruptcy court must approve a plan to reorganize Exactech’s assets and establish how much money will be available to compensate patients. Under Exactech’s revised bankruptcy plan, the company is permitted to sell its assets and will establish a litigation trust to handle claims from patients harmed by the defective implants.
The litigation trust will be funded with money from the asset sales and will be responsible for evaluating and paying patient claims. This process means that instead of suing Exactech directly, patients’ claims will be evaluated by the trust, which has a fixed amount of money to distribute. The bankruptcy process can extend the timeline for compensation, as the trust must be established, funded, and then begin accepting and processing claims. Many patients have found this delay frustrating, as they need compensation now to pay for revision surgeries and medical costs rather than waiting additional years.
UPCOMING BELLWETHER TRIALS AND THE PATH FORWARD
The litigation is moving forward through a series of “bellwether trials,” which are representative cases selected to be tried first. The results of these trials will heavily influence whether both sides are willing to settle the remaining cases or whether more trials will follow. The Tarloff trial is scheduled to begin on July 6, 2026, and the Larson trial has been rescheduled to September 29, 2026. These cases will be closely watched by attorneys and the court, as they will provide the first jury determinations about whether Exactech is liable and what damages patients are entitled to receive.
Bellwether trials can accelerate settlement negotiations significantly. If plaintiffs’ attorneys win the first trials or secure substantial jury verdicts, Exactech’s insurance carriers and the litigation trust may become more willing to settle remaining cases, since the cost of trying each case individually would be prohibitive. Conversely, if Exactech prevails in these early trials, settlement discussions may slow as the company gains negotiating use. The outcomes of the Tarloff and Larson trials will likely determine whether the remaining 1,838 federal cases and 700+ state cases will be settled relatively quickly or whether individual trials will continue for years to come. Patients watching these trials should understand that their own cases may take a different path, as each individual situation has unique facts and damages.
You Might Also Like
- Zantac Ranitidine Cancer Contamination Mass Tort Litigation
- Tylenol Acetaminophen Autism ADHD Pregnancy Mass Tort Litigation
- Tepezza Hearing Loss Mass Tort Litigation
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: